Despite no changes in tumor growth in the SCLC-A xenografts, western blot and IHC analysis of tumors confirmed on-target drug activity of AU-24118 as indicated by efficient loss of SMARCA4, SMARCA2, and PBRM1 (Fig. 3C, Fig. S5D). This evidence concerns the gene SMARCA4 and neoplasm.